NCT01254565View on ClinicalTrials.gov

Safety, Tolerability and Efficacy of Etelcalcetide in Hemodialysis Patients With Secondary Hyperparathyroidism

PHASE2CompletedINTERVENTIONAL
Enrollment

87

Participants

Timeline

Start Date

February 20, 2011

Primary Completion Date

July 31, 2011

Study Completion Date

August 24, 2011

Conditions
Secondary Hyperparathyroidism
Interventions
DRUG

Etelcalcetide

Administered intravenously (IV) at the end of hemodialysis

DRUG

Placebo

Administered intravenously at the end of hemodialysis

Trial Locations (13)

19106

Philadelphia

23320

Chesapeake

31217

Macon

55430

Brooklyn Center

71101

Shreveport

77004

Houston

77099

Houston

80218

Denver

90262

Lynwood

91702

Azusa

92123

San Diego

92505

Riverside

92626

Costa Mesa

Sponsors
All Listed Sponsors
lead

KAI Pharmaceuticals

INDUSTRY

NCT01254565 - Safety, Tolerability and Efficacy of Etelcalcetide in Hemodialysis Patients With Secondary Hyperparathyroidism | Biotech Hunter | Biotech Hunter